Effects of an eight-week supervised, structured lifestyle modification programme on anthropometric, metabolic and cardiovascular risk factors in severely obese adults

Crowe, Catherine; Gibson, Irene; Cunningham, Katie; Kerins, Claire; Costello, Caroline; Windle, Jane; O′Shea, Paula M.; Hynes, Mary; McGuire, Brian; Kilkelly, Katriona; Griffin, Helena; O′Brien, Tim; Jones, Jenni; Finucane, Francis M

doi:10.1186/s12902-015-0038-x

Table 2 Baseline and follow-up anthropometric and metabolic characteristics of 150 severely obese adults completing the Croi CLANN programme

From: Effects of an eight-week supervised, structured lifestyle modification programme on anthropometric, metabolic and cardiovascular risk factors in severely obese adults

Variable	N	Baseline	Follow-up	Difference		P-value
		Mean ± SD	Mean ± SD	Mean	95 % Confidence Interval
Weight (kg)	150	129.6 ± 29.5	126.9 ± 26.1	−2.7	[−3.4, −2.0]	<0.001
BMI (kg/m²)	150	46.3 ± 8.3	44.9 ± 9.0	−1.4	[−2.1, −0.7]	<0.001
Waist (cm) - women	93	133.3 ± 17.1	129.3 ± 17.5	−3.7	[−4.9, −2.4]	<0.001
Waist (cm) – men	50	143.8 ± 19.0	135.1 ± 17.9	−8.0	[−10.5, −5.4]	<0.001
SBP (mmHg)	144	135.0 ± 16.2	131.6 ± 17.1	−3.3	[−5.8, −0.8]	0.009
DBP (mmHg)	144	84.7 ± 10.2	81.4 ± 10.9	−3.2	[−4.9, −1.6]	<0.001
SBP (mmHg) ^a	71	145.5 ± 14.8	138.2 ± 17.3	−7.3	[−11.3, −3.3]	<0.001
DBP (mmHg)^a	71	91.7 ± 8.0	85.7 ± 11.3	−6.0	[−8.5, −3.5]	<0.001
HbA1c (mmol/mol)	114	42 (37, 60)	41 (37, 53)	0	[−2, 0]	0.007
HbA1c (mmol/mol)^b	51	61 (49, 71)	59 (45, 66)	−3	[−5, 0]	0.006
Total Cholesterol (mmol/L)	145	4.7 ± 1.1	4.5 ± 1.0	−0.2	[−0.3, −0.1]	0.001
LDL Cholesterol (mmol/L)	138	2.7 ± 1.0	2.6 ± 0.9	−0.1	[−0.2, 0.0]	0.05
HDL Cholesterol (mmol/L)	145	1.2 ± 0.3	1.1 ± 0.3	−0.02	[−0.04, 0.01]	0.16
Triglycerides (mmol/L)	145	1.6 (1.1, 2.2)	1.4 (1.0, 1.9)	−0.1	[−0.2, −0.01]	<0.001
Total Cholesterol (mmol/L) ^c	62	5.8 ± 0.8	5.2 ± 0.9	−0.6	[−0.8, −0.4]	<0.001
LDL Cholesterol (mmol/L) ^c	62	3.8 ± 0.8	3.4 ± 0.7	−0.4	[−0.6, −0.2]	<0.001
Triglycerides (mmol/L)^c	62	2.2 (1.9, 2.8)	1.9 (1.4, 2.8)	−0.4	[−0.6, −0.03]	<0.001
Metres scored on ISWT (m)	133	295 ± 130	350 ± 153	53	[41, 66]	<0.001
METs achieved on ISWT (MET)	133	3.5 ± 0.9	3.8 ± 1.3	0.4	[0.3, 0.6]	<0.001
Estimated MET max (MET)	133	5.9 ± 1.7	6.8 ± 2.1	0.9	[0.6, 1.1]	<0.001
HRWSI	133	16.9 ± 4.3	15.5 ± 3.6	−1.4	[−1.9, −0.9]	<0.001
Functional limitations score	83	20.5 ± 5.5	22.5 ± 5.3	2.0	[1.1, 2.9]	<0.001
Anxiety score	110	7 (5, 11)	7 (4, 10)	−1	[−2, 0]	<0.001
Depression score	110	8 (5, 11)	4 (2, 7)	−2	[−3, −1]	<0.001
Dartmouth Coop score	110	26 ± 6	23 ± 7	−3	[−4, −2]	<0.001
EQ-VAS	110	53 ± 22	60 ± 20	8	[4, 11]	<0.001
Antiplatelet agents (%)	150	27.4	27.4	0	[−0.7, 0.7]	1.0
Statins (%)	150	34.3	34.3	0	[−0.7, 0.7]	1.0
ACEI/ ARB (%)	150	38.5	39.2	0.7	[−2.4, 3.8]	1.0
Betablockers (%)	150	17.6	17.6	0	[−0.7, 0.7]	1.0
Calcium channel blockers (%)	150	22.6	21.9	−0.7	[−2.7, 1.3]	1.0

Data are presented as mean ± standard deviation or as median (interquartile range)
^aDenotes subgroup with elevated blood pressure at baseline assessment (>140/85 mmHg with diabetes or >140/90 with no diabetes)
^bDenotes subgroup with prevalent type 2 diabetes at baseline
^cDenotes subgroup not meeting that specific lipid subtype target at baseline [21]

Back to article page

ISSN: 1472-6823

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Endocrine Disorders

Contact us